## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Filed by the Registrant [X] Filed by a Party other than the Registrant []

Check the appropriate box:

[] Preliminary Proxy Statement

- [] Confidential, for Use of the Commission Only
- [] Definitive Proxy Statement

[x] Definitive Additional Materials

[] Soliciting Material Under Rule 14a-12

#### NEXIMMUNE, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- [X] No fee required.
- [] Fee previously paid with preliminary materials.
- [] Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.





D81707-P73276

#### You invested in NEXIMMUNE, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 13, 2022.

#### Get informed before you vote

View the Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 30, 2022. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



\*Please check the meeting materials for any special requirements for meeting attendance.

# THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Vo	ing Items	Board Recommends
1.	Election of Directors Nominees: 01) Paul D'Angio, R.P.H., M.S.J. 02) Zhengbin (Bing) Yao, Ph.D.	🛇 For
2.	To ratify the appointment of Ernst & Young LLP as NexImmune, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2022.	• For
N	NOTE: Such other business as may properly come before the meeting or any adjournment thereof.	
	Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-de	ivery".

D81708-P73276